Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)

NCT03337542 is registered in ClinicalTrials.gov with Aimmune Therapeutics, Inc. as lead sponsor.

NCT NCT03337542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03337542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)
Lead sponsor
Aimmune Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 18, 2017
Completion date
September 20, 2019
Enrollment
243 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy